Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652040 · ClinicalTrials.gov registry record · Phase 2
Resistance Training and Testosterone After Spinal Cord Injury
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01652040: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01652040 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01652040, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this proposal is to investigate the efficacy of a complimentary approach of evoked resistance training and testosterone replacement therapy on the changes in body composition and metabolic profile after SCI. The proposed method could become a recommended and simple intervention especially for individuals with limited access and poor tolerance to exercise. The rationale is based on the evidence that individuals with SCI experience decline in anabolic hormones which may be responsible for the deterioration in body composition and metabolic profiles and leads to increase obesity, type 2 diabetes mellitus, dyslipidemia and subsequently cardiovascular disease. The designed study will provide explanation to the adaptations in the energy source of the muscle cells in response to training.
Interventions
- DEVICE Resistance Training and Testosterone Patches
- DRUG Testosterone Patches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-07-02 |
| Est. Completion | 2017-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652040
The ClinicalTrials.gov registry entry for NCT01652040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Resistance Training and Testosterone Patches is the first listed.
NCT01652040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01652040 about?
NCT01652040 is a clinical study titled "Resistance Training and Testosterone After Spinal Cord Injury". The goal of this proposal is to investigate the efficacy of a complimentary approach of evoked resistance training and testosterone replacement therapy on the changes in body composition and metabolic profile after SCI. The proposed method could become a recommended and simple intervention especiall...
What is the current status of trial NCT01652040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2012-07-02. Estimated completion is 2017-12-30.
What interventions are being tested in trial NCT01652040?
The interventions under investigation include: Resistance Training and Testosterone Patches (DEVICE), Testosterone Patches (DRUG).
Who is sponsoring clinical trial NCT01652040?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.